农牧区蒙古族高血压和高血压前期的危险因素及其与脑卒中发病的关系
|
摘要
研究目的:1.了解农牧区蒙古族人群中高血压前期以及高血压的现患率,比较高血压前期与高血压者中心血管疾病危险因素及其聚集程度。2.探讨炎症和内皮功能异常与高血压前期和高血压的关联关系及关联强度。3.阐明高血压前期人群是否比血压正常人群有更高的脑卒中发病风险。4.阐明炎症和内皮功能异常是否会增加脑卒中发病风险。
对象与方法:
1.基线研究:2002-2003年选择内蒙古通辽市科左后旗朝鲁吐乡和奈曼旗固日班花乡共32村作为调查现场,将居住在该地20岁及以上成年蒙古族人作为研究对象。采用统一制定的调查问卷,按标准化调查方法,由培训过的医师对研究对象进行调查、血压测量、身体指标测量和血标本采集。(1)现场调查内容包括:人口统计学特征、高血压家族史、吸烟和饮酒情况等;三次血压测量;身体指标测量:身高、体重、腰围及臀围。(2)实验室检测包括:空腹血糖、胰岛素、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白A1(ApoA1)、载脂蛋白B(ApoB)、C-反应蛋白(CRP)、细胞间黏附分子-1(ICAM-1)、E-选择素(E-selectin)、血管紧张素II(AngII)和血浆肾素活性(PRA)。
2.随访研究:分别于2008年10月和2009年7-8月对参与基线研究的对象进行了随访,结局事件定义为从基线到最后一次随访期间首次发生的脑卒中事件。采取入户调查和查阅监测资料、医院病历记录相结合的方法,采用标准设计的调查表,对每位研究对象进行调查,收集观察期内发生脑卒中事件的相关资料。
3.统计分析:采用Epidata3.0软件建立数据库,所有调查表经过双录入后进行核对,应用SAS 9.1软件进行统计分析,检验水准α设为0.05。
结果:现场内共有2589人参与了本研究,其中男性有1064人,女性1525人。年龄最小为20岁,最大为84岁,平均年龄为46.5岁。
1.该地高血压前期现患率为38.39%,其中男性现患率为38.44%,女性现患率为38.36%;高血压现患率为37.39%,其中男性现患率为45.58%,女性现患率为31.67%。
2.高血压前期人群中饮酒(31.29%)、超重或肥胖(23.34%)、中心肥胖(37.63%)、血脂异常(25.26%)、空腹血糖受损或糖尿病(17.56%)、高CRP(23.90%)的比例均高于正常血压者;同样,高血压人群中饮酒(44.32%)、超重或肥胖(37.16%)、中心肥胖(53.52%)、血脂异常(37.89%)、空腹血糖受损或糖尿病(25.60%)、高CRP(32.63%)的比例高于血压前期及血压正常者。
3.多因素的logistic回归分析结果表明,高血压前期与年龄增加、男性、超重、肥胖、高TG、高ApoB和高AngII相关联,其OR值及95%可信区间(95%CI)分别为:1.03(1.02 ~1.04)、2.04(1.50 ~2.79)、1.96(1.23 ~3.13)、2.58(1.18 ~5.52)、1.64(1.09 ~2.47)、1.99(1.03 ~3.84)和1.39(1.01 ~1.89);而高血压与年龄、男性、高血压家族史、重度饮酒、超重、肥胖、高甘油三酯、高ApoB、心动过速、高AngII和CRP存在正的关联,其OR(95%CI)分别为1.09(1.07~1.10)、2.05(1.44~2.89)、5.83(3.51~9.69)、2.10(1.31~3.35)、3.41(2.02~5.73)、8.16(3.69~18.01)、2.13(1.39 ~3.25)、2.07(1.00~4.28)、4.16 (1.29~13.44)、2.36(1.65 ~3.35)和1.57(1.03~2.37)。
4.高血压前期人群超重或肥胖、中心肥胖、空腹血糖受损或糖尿病、血脂异常等4个因素中2个及2个以上因素的聚集率(31.39%)大于血压正常者(21.25%),高血压人群(49.43%)大于高血压前期及血压正常者。调整年龄、性别等其他因素后,有1个、2个及≥3个危险因素聚集的人群患有高血压前期的危险分别是无危险因素聚集人群的1.56(1.19~2.06)、1.89(1.38~2.59)和2.57(1.61~4.09)倍,患有高血压的危险分别为1.98(1.44~2.73)、3.46(2.47~4.97)和7.58(4.69~12.26)。
5.高血压前期人群高AngII、高CRP、高ICAM-1和低PRA等4个因素中有2个及2个以上因素的聚集率(22.36%)大于血压正常者(13.40%),高血压人群(37.94%)大于高血压前期及血压正常者。调整年龄、性别等其他因素后,有1个、2个及≥3个危险因素聚集的人群患有高血压前期的危险分别是无危险因素聚集人群的1.17(0.93~1.49)、1.40(0.99~1.97)和2.61(1.17~5.82)倍,患有高血压的危险分别为0.85(0.64~1.13)、1.42(1.04~2.20)、4.98(2.26~11.00)。
6.在7年的随访中,2589个研究对象中新发脑卒中78例,其中41例为缺血性脑卒中,35例为出血性脑卒中,2例分型不清。脑卒中的发病密度为476.91/10万人年,其中男性脑卒中的发病密度为809.19/10万人年,女性发病密度为255.28/10万人年;缺血性脑卒中的发病密度为250.80/10万人年,出血性脑卒中的发病密度为213.38/10万人年。
7.正常血压者和高血压前期人群脑卒中的发病密度分别为25/10万人年和282/10万人年。与正常血压者相比,高血压前期者发生脑卒中的风险比为11.3。高血压前期人群中发生脑卒中的归因危险度百分比为91%、人群归因危险度百分比为20%;高血压人群脑卒中的发病密度为987/10万人年,高于高血压前期人群和正常血压者。与血压正常者相比,高血压者发生脑卒中的风险比为39.7。高血压中发生脑卒中的归因危险度百分比为97%,人群归因危险度百分比为74%。
8.根据基线时CRP的四分位数把人群分成四组,以小于下四分位数者为参比组,CRP最高分位数组发生缺血性脑卒中的风险比(HR)为2.96(1.17~7.46),但是在调整年龄、性别后,HR值(1.89,95%CI:0.75~4.76)无统计学意义。而基线血清中的AngII、ICAM-1、E-selectin与脑卒中的发病尚未发现有统计学意义的关联。
结论:
1.内蒙古农牧区蒙古族人群中高血压前期和高血压的现患率均较高。高血压前期者心血管疾病危险因素的水平以及危险因素的聚集程度均高于血压正常者。因此,在高血压前期阶段已经具有心血管危险因素的存在和聚集。
2.高水平的CRP和AngII者患高血压前期和高血压的危险性均有所增加,炎症或内皮功能受损在高血压的发展过程中可能发挥一定的作用。
3.现场内的蒙古族居民具有较高的脑卒中发病率,脑卒中已成为威胁当地蒙古族居民健康与生命的重要疾病及公共卫生问题。
4.与正常血压者相比,基线高血压前期和高血压人群具有较高的脑卒中发病率及风险比。高血压前期人群已具有发生脑卒中的较高风险,是脑卒中发病的重要危险因素。
Objective: 1. To investigate the prevalence of pre-hypertension and hypertension in Mongolian population lived in the agricultural and pastoral areas, and to compare cardiovascular risk factors, clustering of these factors between pre-hypertension and hypertension. 2. To explore association between inflammation and endothelial dysfunction biomarkers and pre-hypertension and hypertension. 3. To study whether pre-hypertension individuals have more hazards developing to stroke. 4. To study whether status of inflammation and endothelial dysfunction was associated with increased risk of stroke.
Subjects and methods:
1. Baseline investigation: A cross sectional survey was conducted between 2002 and 2003. In the survey, study participants aged 20 years and older were recruited from 32 villages in 2 adjacent townships located in Kezuohou Banner (county) and Naiman Banner in Inner Mongolia, and they were administered interview using a standard questionnaire, and the related physical examination and blood samples collection were conducted by trained staffs.
(1) Field survey
Data on demographic characteristics, family history of hypertension, smoking and alcohol consumption were obtained. Height, weight, waist circumference, hip circumference and three blood pressures were measured for all participants.
(2)Laboratory tests
Fasting plasma glucose(FPG), insulin, triglyceride(TG), total cholesterol(TC), high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1(ApoA1), apolipoprotein B(ApoB), C-reactive protein (CRP), E-selectin, intercellular adhesion molecules-1(ICAM-1), plasma rennin activity (PRA) and angiotensin II(AngII) were detected for all participants.
2. Survey follow-up study
In October 2008 and July to August 2009, follow-up surveys were conducted for the subjects involved in a baseline study. Failure event is defined as the first occurrence of stroke during the time from the baseline to the last follow-up. We interviewed subjects by household, reviewed monitoring data and hospital medical records to investigate stroke events using standard questionnaires.
3. Statistical analysis
Epidata3.0 software was used to establish a database, and all questionnaires were input after checking by two individuals. All p-values were based on a 2-sided test and a significance level of 0.05, and statistical analysis was conducted using SAS 9.1 statistical software.
Results:
A total of 2589 participants aged 20-84 years old, 1064 males and 1525 females, were included in the analysis.
1. In the study, prehypertensives accounted for 38.39% among all participants, 38.44% in males and 38.36% in females. Hypertensives accounted for 37.39% among all participants, 45.58% in males and 31.67% in females.
2. Prehypertensives had higher proportions of individuals with alcohol consumption (31.29%), overweight or obesity (23.34%), central obesity (37.63%), hyperlipidemia (25.26%), impaired fasting glucose or diabetes (17.56%) and high CRP (23.9%) than normotensives. Similarly, hypertensives had higher proportions of individuals with alcohol consumption (44.32%), overweight or obesity (37.16%), central obesity (53.52%), hyperlipidemia (37.89%), impaired fasting glucose or diabetes (25.60%) and high CRP (32.63%) than pre-hypertensives and normotensives
3. Multivariate logistic regression analysis showed that pre-hypertension was associated with increasing age, male, overweight, obesity, high triglycerides, high Apolipoprotein B and high angiotensin II, and the odd ratios (ORs) and 95% confidence intervals (95% CIs) were as follows: 1.03(1.02-1.04), 2.04(1.50-2.79), 1.96(1.23 -3.13), 2.58(1.18 -5.52), 1.64(1.09-2.47), 1.99(1.03 -3.84) and 1.39(1.01 -1.89), respectively. Hypertension was positively associated with aging, male, family history of hypertension, heavy drinking, overweight, obesity, high triglycerides, Apolipoprotein B, heart rate, angiotensin II and CRP, and ORs (95%CIs) were 1.09(1.07-1.10), 2.05 (1.44 -2.89), 5.83(3.51-9.69), 2.10(1.31-3.35), 3.41(2.02-5.73), 8.16(3.69-18.01), 2.13 (1.39-3.25), 2.07(1.00-4.28), 4.16(1.29-13.44), 2.36(1.65-3.35) and 1.57(1.03-2.37), respectively.
4. Prehypertensives had high clustering proportion (31.39%) of≥2 risk factors, including overweight or obesity, central obesity, impaired fasting glucose or diabetes and hyperlipidemia, than that in normotensives (21.25%), and hypertensives had high clustering proportion (49.43%) than prehypertensives and normotenives. Compared with none risk factors clustering group, 1, 2 and≥3 factors clustering groups had the ORs (95%CIs) of 1.56(1.19-2.06), 1.89(1.38-2.59) and 2.57(1.61-4.09) for pre-hypertension, respectively; and ORs(95%CIs) of 1.98(1.44-2.73), 3.46(2.47-4.97) and 7.58 (4.69-12.26) for hypertension, respectively.
5. Prehypertensives had high clustering proportion (22.36%) of≥2 risk factors, including high levels of angiotensin II, high CRP, ICAM-1 and low levels of PRA, than that in normotensives (13.40%), and hypertensives had high clustering proportion (37.94%) of the biomarkers than prehypertensives and normotensives. Compared with none risk factors clustering group, 1, 2 and≥3 biomarkers clustering groups had the ORs (95%CIs) of 1.17(0.93-1.49), 1.40(0.99-1.97) and 2.61(1.17-5.82) for pre-hypertension, respectively; and ORs (95%CIs) of 0.85(0.64-1.13), 1.42(1.04-2.20) and 4.98 (2.26-11.00) for hypertension , respectively.
6. During follow-up, 78 new stroke cases occurred among 2589, 41 cases were ischemic stroke and 35 cases were hemorrhagic stroke, and 2 cases of sub-type were unknown. The incidence density of stroke was 476.91/100 000 person-years, which were 809.19/100 000 person-years in men and 255.28/100 000 person-years in women. The incidence densities of ischemic and hemorrhagic stroke were 250.80/100000 person-years and 213.38/100 000 person-years, respectively.
7. The incidence density of stroke was 25/100 000 person-years in normotension group, and 282/100 000 person-years in pre-hypertension group. Compared with normotensives, prehypertensive individuals had a hazard ratio (HR) of 11.3 for stroke. Attributable risk percent (ARP) was 91% and population attributable risk percent (PARP) was 20% for stroke in pre-hypertensive population. The incidence density of stroke was 987/100 000 person-years in hypertension group. And the HR for stroke was 39.7, compared to normotensives. Moreover, ARP was 97% and PARP was 74% for stroke in hypertensives.
8. The population was divided into four groups according to baseline CRP quartile, and the lowest quartile as the reference group, the highest group had the HR of 2.96(95%CI: 1.17-7.46) for ischemic stroke, but adjusted for age and sex, HR value(1.89, 95%CI: 0.75-4.76)was no more statistically significant. Association between the baseline serums AngII, ICAM-1, E-selectin and the incidence of stroke has not been found statistically significant.
Conclusion:
1. The prevalence rates of pre-hypertension and hypertension are relatively high in Mongolia population. Pre-hypertensive population has higher levels and aggregation extents of cardiovascular risk factors than those with normotension. Thus, cardiovascular risk factors and clustering of these factors are existed in the stage of pre-hypertension.
2.Individuals with high levels of CRP and AngII have increased risk of suffering from pre-hypertension, inflammation or endothelial dysfunction may play a role in the development of hypertension.
3. The incidence of stroke is high in the study, and Stroke has become an important disease and public health issues threaten to the health and lives of local Mongolian.
4. Compared with normal blood pressure, baseline pre-hypertension and hypertension groups have higher incidences of stroke and hazard ratios for stroke. So, pre-hypertensive group had higher risk of stroke occurrence, and pre-hypertension is a major risk factor for stroke.
对象与方法:
1.基线研究:2002-2003年选择内蒙古通辽市科左后旗朝鲁吐乡和奈曼旗固日班花乡共32村作为调查现场,将居住在该地20岁及以上成年蒙古族人作为研究对象。采用统一制定的调查问卷,按标准化调查方法,由培训过的医师对研究对象进行调查、血压测量、身体指标测量和血标本采集。(1)现场调查内容包括:人口统计学特征、高血压家族史、吸烟和饮酒情况等;三次血压测量;身体指标测量:身高、体重、腰围及臀围。(2)实验室检测包括:空腹血糖、胰岛素、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白A1(ApoA1)、载脂蛋白B(ApoB)、C-反应蛋白(CRP)、细胞间黏附分子-1(ICAM-1)、E-选择素(E-selectin)、血管紧张素II(AngII)和血浆肾素活性(PRA)。
2.随访研究:分别于2008年10月和2009年7-8月对参与基线研究的对象进行了随访,结局事件定义为从基线到最后一次随访期间首次发生的脑卒中事件。采取入户调查和查阅监测资料、医院病历记录相结合的方法,采用标准设计的调查表,对每位研究对象进行调查,收集观察期内发生脑卒中事件的相关资料。
3.统计分析:采用Epidata3.0软件建立数据库,所有调查表经过双录入后进行核对,应用SAS 9.1软件进行统计分析,检验水准α设为0.05。
结果:现场内共有2589人参与了本研究,其中男性有1064人,女性1525人。年龄最小为20岁,最大为84岁,平均年龄为46.5岁。
1.该地高血压前期现患率为38.39%,其中男性现患率为38.44%,女性现患率为38.36%;高血压现患率为37.39%,其中男性现患率为45.58%,女性现患率为31.67%。
2.高血压前期人群中饮酒(31.29%)、超重或肥胖(23.34%)、中心肥胖(37.63%)、血脂异常(25.26%)、空腹血糖受损或糖尿病(17.56%)、高CRP(23.90%)的比例均高于正常血压者;同样,高血压人群中饮酒(44.32%)、超重或肥胖(37.16%)、中心肥胖(53.52%)、血脂异常(37.89%)、空腹血糖受损或糖尿病(25.60%)、高CRP(32.63%)的比例高于血压前期及血压正常者。
3.多因素的logistic回归分析结果表明,高血压前期与年龄增加、男性、超重、肥胖、高TG、高ApoB和高AngII相关联,其OR值及95%可信区间(95%CI)分别为:1.03(1.02 ~1.04)、2.04(1.50 ~2.79)、1.96(1.23 ~3.13)、2.58(1.18 ~5.52)、1.64(1.09 ~2.47)、1.99(1.03 ~3.84)和1.39(1.01 ~1.89);而高血压与年龄、男性、高血压家族史、重度饮酒、超重、肥胖、高甘油三酯、高ApoB、心动过速、高AngII和CRP存在正的关联,其OR(95%CI)分别为1.09(1.07~1.10)、2.05(1.44~2.89)、5.83(3.51~9.69)、2.10(1.31~3.35)、3.41(2.02~5.73)、8.16(3.69~18.01)、2.13(1.39 ~3.25)、2.07(1.00~4.28)、4.16 (1.29~13.44)、2.36(1.65 ~3.35)和1.57(1.03~2.37)。
4.高血压前期人群超重或肥胖、中心肥胖、空腹血糖受损或糖尿病、血脂异常等4个因素中2个及2个以上因素的聚集率(31.39%)大于血压正常者(21.25%),高血压人群(49.43%)大于高血压前期及血压正常者。调整年龄、性别等其他因素后,有1个、2个及≥3个危险因素聚集的人群患有高血压前期的危险分别是无危险因素聚集人群的1.56(1.19~2.06)、1.89(1.38~2.59)和2.57(1.61~4.09)倍,患有高血压的危险分别为1.98(1.44~2.73)、3.46(2.47~4.97)和7.58(4.69~12.26)。
5.高血压前期人群高AngII、高CRP、高ICAM-1和低PRA等4个因素中有2个及2个以上因素的聚集率(22.36%)大于血压正常者(13.40%),高血压人群(37.94%)大于高血压前期及血压正常者。调整年龄、性别等其他因素后,有1个、2个及≥3个危险因素聚集的人群患有高血压前期的危险分别是无危险因素聚集人群的1.17(0.93~1.49)、1.40(0.99~1.97)和2.61(1.17~5.82)倍,患有高血压的危险分别为0.85(0.64~1.13)、1.42(1.04~2.20)、4.98(2.26~11.00)。
6.在7年的随访中,2589个研究对象中新发脑卒中78例,其中41例为缺血性脑卒中,35例为出血性脑卒中,2例分型不清。脑卒中的发病密度为476.91/10万人年,其中男性脑卒中的发病密度为809.19/10万人年,女性发病密度为255.28/10万人年;缺血性脑卒中的发病密度为250.80/10万人年,出血性脑卒中的发病密度为213.38/10万人年。
7.正常血压者和高血压前期人群脑卒中的发病密度分别为25/10万人年和282/10万人年。与正常血压者相比,高血压前期者发生脑卒中的风险比为11.3。高血压前期人群中发生脑卒中的归因危险度百分比为91%、人群归因危险度百分比为20%;高血压人群脑卒中的发病密度为987/10万人年,高于高血压前期人群和正常血压者。与血压正常者相比,高血压者发生脑卒中的风险比为39.7。高血压中发生脑卒中的归因危险度百分比为97%,人群归因危险度百分比为74%。
8.根据基线时CRP的四分位数把人群分成四组,以小于下四分位数者为参比组,CRP最高分位数组发生缺血性脑卒中的风险比(HR)为2.96(1.17~7.46),但是在调整年龄、性别后,HR值(1.89,95%CI:0.75~4.76)无统计学意义。而基线血清中的AngII、ICAM-1、E-selectin与脑卒中的发病尚未发现有统计学意义的关联。
结论:
1.内蒙古农牧区蒙古族人群中高血压前期和高血压的现患率均较高。高血压前期者心血管疾病危险因素的水平以及危险因素的聚集程度均高于血压正常者。因此,在高血压前期阶段已经具有心血管危险因素的存在和聚集。
2.高水平的CRP和AngII者患高血压前期和高血压的危险性均有所增加,炎症或内皮功能受损在高血压的发展过程中可能发挥一定的作用。
3.现场内的蒙古族居民具有较高的脑卒中发病率,脑卒中已成为威胁当地蒙古族居民健康与生命的重要疾病及公共卫生问题。
4.与正常血压者相比,基线高血压前期和高血压人群具有较高的脑卒中发病率及风险比。高血压前期人群已具有发生脑卒中的较高风险,是脑卒中发病的重要危险因素。
Objective: 1. To investigate the prevalence of pre-hypertension and hypertension in Mongolian population lived in the agricultural and pastoral areas, and to compare cardiovascular risk factors, clustering of these factors between pre-hypertension and hypertension. 2. To explore association between inflammation and endothelial dysfunction biomarkers and pre-hypertension and hypertension. 3. To study whether pre-hypertension individuals have more hazards developing to stroke. 4. To study whether status of inflammation and endothelial dysfunction was associated with increased risk of stroke.
Subjects and methods:
1. Baseline investigation: A cross sectional survey was conducted between 2002 and 2003. In the survey, study participants aged 20 years and older were recruited from 32 villages in 2 adjacent townships located in Kezuohou Banner (county) and Naiman Banner in Inner Mongolia, and they were administered interview using a standard questionnaire, and the related physical examination and blood samples collection were conducted by trained staffs.
(1) Field survey
Data on demographic characteristics, family history of hypertension, smoking and alcohol consumption were obtained. Height, weight, waist circumference, hip circumference and three blood pressures were measured for all participants.
(2)Laboratory tests
Fasting plasma glucose(FPG), insulin, triglyceride(TG), total cholesterol(TC), high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1(ApoA1), apolipoprotein B(ApoB), C-reactive protein (CRP), E-selectin, intercellular adhesion molecules-1(ICAM-1), plasma rennin activity (PRA) and angiotensin II(AngII) were detected for all participants.
2. Survey follow-up study
In October 2008 and July to August 2009, follow-up surveys were conducted for the subjects involved in a baseline study. Failure event is defined as the first occurrence of stroke during the time from the baseline to the last follow-up. We interviewed subjects by household, reviewed monitoring data and hospital medical records to investigate stroke events using standard questionnaires.
3. Statistical analysis
Epidata3.0 software was used to establish a database, and all questionnaires were input after checking by two individuals. All p-values were based on a 2-sided test and a significance level of 0.05, and statistical analysis was conducted using SAS 9.1 statistical software.
Results:
A total of 2589 participants aged 20-84 years old, 1064 males and 1525 females, were included in the analysis.
1. In the study, prehypertensives accounted for 38.39% among all participants, 38.44% in males and 38.36% in females. Hypertensives accounted for 37.39% among all participants, 45.58% in males and 31.67% in females.
2. Prehypertensives had higher proportions of individuals with alcohol consumption (31.29%), overweight or obesity (23.34%), central obesity (37.63%), hyperlipidemia (25.26%), impaired fasting glucose or diabetes (17.56%) and high CRP (23.9%) than normotensives. Similarly, hypertensives had higher proportions of individuals with alcohol consumption (44.32%), overweight or obesity (37.16%), central obesity (53.52%), hyperlipidemia (37.89%), impaired fasting glucose or diabetes (25.60%) and high CRP (32.63%) than pre-hypertensives and normotensives
3. Multivariate logistic regression analysis showed that pre-hypertension was associated with increasing age, male, overweight, obesity, high triglycerides, high Apolipoprotein B and high angiotensin II, and the odd ratios (ORs) and 95% confidence intervals (95% CIs) were as follows: 1.03(1.02-1.04), 2.04(1.50-2.79), 1.96(1.23 -3.13), 2.58(1.18 -5.52), 1.64(1.09-2.47), 1.99(1.03 -3.84) and 1.39(1.01 -1.89), respectively. Hypertension was positively associated with aging, male, family history of hypertension, heavy drinking, overweight, obesity, high triglycerides, Apolipoprotein B, heart rate, angiotensin II and CRP, and ORs (95%CIs) were 1.09(1.07-1.10), 2.05 (1.44 -2.89), 5.83(3.51-9.69), 2.10(1.31-3.35), 3.41(2.02-5.73), 8.16(3.69-18.01), 2.13 (1.39-3.25), 2.07(1.00-4.28), 4.16(1.29-13.44), 2.36(1.65-3.35) and 1.57(1.03-2.37), respectively.
4. Prehypertensives had high clustering proportion (31.39%) of≥2 risk factors, including overweight or obesity, central obesity, impaired fasting glucose or diabetes and hyperlipidemia, than that in normotensives (21.25%), and hypertensives had high clustering proportion (49.43%) than prehypertensives and normotenives. Compared with none risk factors clustering group, 1, 2 and≥3 factors clustering groups had the ORs (95%CIs) of 1.56(1.19-2.06), 1.89(1.38-2.59) and 2.57(1.61-4.09) for pre-hypertension, respectively; and ORs(95%CIs) of 1.98(1.44-2.73), 3.46(2.47-4.97) and 7.58 (4.69-12.26) for hypertension, respectively.
5. Prehypertensives had high clustering proportion (22.36%) of≥2 risk factors, including high levels of angiotensin II, high CRP, ICAM-1 and low levels of PRA, than that in normotensives (13.40%), and hypertensives had high clustering proportion (37.94%) of the biomarkers than prehypertensives and normotensives. Compared with none risk factors clustering group, 1, 2 and≥3 biomarkers clustering groups had the ORs (95%CIs) of 1.17(0.93-1.49), 1.40(0.99-1.97) and 2.61(1.17-5.82) for pre-hypertension, respectively; and ORs (95%CIs) of 0.85(0.64-1.13), 1.42(1.04-2.20) and 4.98 (2.26-11.00) for hypertension , respectively.
6. During follow-up, 78 new stroke cases occurred among 2589, 41 cases were ischemic stroke and 35 cases were hemorrhagic stroke, and 2 cases of sub-type were unknown. The incidence density of stroke was 476.91/100 000 person-years, which were 809.19/100 000 person-years in men and 255.28/100 000 person-years in women. The incidence densities of ischemic and hemorrhagic stroke were 250.80/100000 person-years and 213.38/100 000 person-years, respectively.
7. The incidence density of stroke was 25/100 000 person-years in normotension group, and 282/100 000 person-years in pre-hypertension group. Compared with normotensives, prehypertensive individuals had a hazard ratio (HR) of 11.3 for stroke. Attributable risk percent (ARP) was 91% and population attributable risk percent (PARP) was 20% for stroke in pre-hypertensive population. The incidence density of stroke was 987/100 000 person-years in hypertension group. And the HR for stroke was 39.7, compared to normotensives. Moreover, ARP was 97% and PARP was 74% for stroke in hypertensives.
8. The population was divided into four groups according to baseline CRP quartile, and the lowest quartile as the reference group, the highest group had the HR of 2.96(95%CI: 1.17-7.46) for ischemic stroke, but adjusted for age and sex, HR value(1.89, 95%CI: 0.75-4.76)was no more statistically significant. Association between the baseline serums AngII, ICAM-1, E-selectin and the incidence of stroke has not been found statistically significant.
Conclusion:
1. The prevalence rates of pre-hypertension and hypertension are relatively high in Mongolia population. Pre-hypertensive population has higher levels and aggregation extents of cardiovascular risk factors than those with normotension. Thus, cardiovascular risk factors and clustering of these factors are existed in the stage of pre-hypertension.
2.Individuals with high levels of CRP and AngII have increased risk of suffering from pre-hypertension, inflammation or endothelial dysfunction may play a role in the development of hypertension.
3. The incidence of stroke is high in the study, and Stroke has become an important disease and public health issues threaten to the health and lives of local Mongolian.
4. Compared with normal blood pressure, baseline pre-hypertension and hypertension groups have higher incidences of stroke and hazard ratios for stroke. So, pre-hypertensive group had higher risk of stroke occurrence, and pre-hypertension is a major risk factor for stroke.
引文
1. Kannel WB. Blood pressure as a cardiovascular risk. JAMA 1996; 275: 1571-1576.
2. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular diseases in the Asia-Pacific region. J Hypertens 2003; 21: 707-716.
3. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; 289(19): 2560-2572.
4.中国高血压防治指南修订委员会.中国高血压防治指南2005年修订版[ R] .北京:中国高血压防治指南修订委员会, 2005.
5. Lewington S,Clarke R,Qizilbash N,et al .Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
6.王薇,赵冬,刘静,等.中国35～64岁人群血压水平与10年心血管病发病危险的前瞻性研究.中华内科杂志2004; 43 (10):730-734
7.赵冬,李翠芬,王薇,等.正常高值血压人群10年心血管病发病危险的分析.中华老年心脑血管病杂志2006;8 (11): 730-733.
8.孙佳艺、赵冬、王薇等.北京地区2740人的血压水平(1992-2002)变化情况.高血压杂志2005; 13(2):115-119.
9. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: A cohort study. Lancet 2001; 358: 1682-1686.
10. Ueshima H, Zhang X, Choudhury SR. Epidemiology of hypertension in China and Japan. J Hum Hypertens 2000; 14, 765-769.
11.周慧,胡晓抒,郭志荣登.高血压前期的血压水平与多代谢异常的关系.中华流行病学杂志2005; 26(11):892-896.
12.梁柳娟,梁志忠,邓国任等.社区高血压多代谢异常的横断面研究.现代预防医学2005;32(2):1617-1619.
13. Hsia J, Margolis KL, Eaton CB, et al. Prehypertension and cardiovascular disease risk in the Women’s Health Initiative. Circulation 2007; 115: 855-860.
14. Grotto I, Grossman E, Huerta M, Sharabi Y. Prevalence of prehypertension and associated cardiovascular risk profiles among young Israeli adults. Hypertension 2006; 48: 254–259.
15. Galeen FX. Cell adhesion molecules in hypertension: endothelial markers of vascular injury and predictors of target organ damage? J Hypertens 2002; 20: 871-877.
16.阿祥仁,张鑫生,王立萍.高原地区健康老年人同型半胱氨酸水平与血管内皮细胞功能的相关性.中华老年医学杂志2006; 25(2):123-124.
17.Freestone B, Gustafsson F, Chong AY, Corell P, Kistorp C, Hildebrandt P, Lip GY. Influence of atrial fibrillation on plasma von willebrand factor, soluble E-selectin,and N-terminal pro B-type natriuretic peptide levels in systolic heart failure. Chest 2008; 133(5):1203-1208.
18.Spencer CG, Felmeden DC, Blann AD, Lip GY. Haemorheological, platelet and endothelial indices in relation to global measures of cardiovascular risk in hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. J Intern Med. 2007 ; 261(1): 82-90.
19.Schillaci G, Pirro M, Gemelli F, et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens 2003; 21(10):1841-1846.
20.Bautista LE, Lópex-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens. 2001; 19(5): 857-861.
21. Sung KC, Suh JY, Kim BS, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16(6):429-433.
22. Lakoski SG, Herrington DM, Siscovick DM, Hulley SB. C-reactive protein concentration and incident hypertension in young adults: the CARDIA study. Arch Intern Med 2006; 166(3):345-349.
23. Davey Smith G, Lawlor DA, Harbord R, et al. Association of C-reactive protein with blood pressure and hypertension life course confounding and Mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 2005; 25:1051-1056.
24. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-2951.
25. Miller MA, Kerry SM, Cook DG, Cappuccio FP. Cellular adhesion molecules and blood pressure interaction with sex in a multi-ethnic population. J Hypertens 2004; 22:705–711.
26. DeSouza CA, Dengel DR, Macko RF, Cox K, Seals DR. Elevated evels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens 1997; 10: 1335-1341.
27. He J, Klag MJ, Wu ZL, Whelton PK. Stroke in the People's Republic of China: I. Geographic Variations in Incidence and Risk Factors. Stroke 1995; 26(12):2222-2227.
28. WHO. Global burden of disease 2002: deaths by age, sex and cause for the year 2002. Geneva, Switzerland: Word Health Organization; 2003.
29.Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular disease: Part II: variation in cardiovascular disease by specific ethnic groups and geographic regions strategies. Circulation 2001; 104:2855-2864.
30. Whelton PK, He J. Blood pressure reduction. In Manson JE, Buring JE, Ridker PM, Gaziano JM editors. Clinical trials in cardiovascular disease. 2nd ed. Philadelphia: Elsevier Saunders 1999; 282-296.
31. Zhang, C. The role of inflammatory cytokines in endothelial dysfunction. Basic Research in Cardiology 2008; 103(5): 398-406.
32. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation, Part I. Circulation 2003; 108: 1917-1923.
33. Ridker PM, Hennekens CH, Buring JE, Rifal N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 2000; 342: 836-843.
34. Mulvihill NT, Foley JB. Inflammation in acute coronary syndromes. Heart 2002; 87: 201-204.
35. Lindsberg PJ, Grau AJ. Inflammation and Infections as Risk Factors for Ischemic Stroke. Stroke 2003; 34: 2518-2532
36.Wakugawa Y, Kiyohara Y, Tanizaki Y, et al. C-Reactive Protein and Risk of First-Ever Ischemic and Hemorrhagic Stroke in a General Japanese Population. The Hisayama Study. Stroke 2006; 37:27-32.
37.张永红,佟伟军,张宏伟,等.通辽市农牧区蒙古族居民高血压调查报告.中国公共卫生2003;19(11):1358-1359.
1.丁元林等主编.《卫生统计学》[M].科学出版社2008.
2.中国高血压防治指南修订委员会.中国高血压防治指南2005年修订版[R] .北京:中国高血压防治指南修订委员会, 2005.
3. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; 289(19): 2560-2572.
4.中国疾病控制司编写.中国成人超重和肥胖症预防与控制指南<试行>.中国人民卫生出版社2003.
5.中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南.中华心血管病杂志2007; 35: 390-419.
6. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance andβ2 cell function from fasting plasma glucose and insulin concent rations in man. Diabetologia 1985; 28: 412-419.
7.高惠璇.《SAS系统. SAS/ETS软件使用手册》[M].中国统计出版社2001.
8. Hosmer DW, Lemeshow S. Applied logistic regression, 2nd-edn. New York: John Wiley & Sons; 2000.
9. Spiegelman D, Hertzmark E, Wand HC. Point and interval estimates of partial population attributable risks in cohort studies: examples and software. Cancer Causes Control 2007; 18:571–579.
1. Sun ZQ, Zheng LQ, Wei YD, et al. The Prevalence of Prehypertension and Hypertension Among Rural Adults in Liaoning Province of China. Clin Cardiol. 2007; 30, 183-187.
2. Tsai PS, Ke TL, Huang CJ, Tsai JC, Chen PL. Prevalence and determinants of prehypertension status in the Taiwanese general population. J Hypertens 2005; 23: 1355-13606.
3. Wang Y, Wang Q J. The prevalence of prehypertension and hypertension among US adults according to the New Joint National Committee Guidelines. Arch Intern Med. 2004; 164: 2126-2134.
4. Aekplakorn W, Abbott-Klafter J, Khonputsa P, et al. Prevalence and management of prehypertension and hypertension by geographic regions of Thailand: the Third National Health Examination Survey, 2004. J Hypertens 2008; 26(2):191-198.
5. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: A cohort study. Lancet 2001; 358: 1682- 1686.
6. Sun J , Zhao D, Wang W, Liu J, Wu C, Wang W. The change of blood pressure during ten years (1992-2002) in 2740 subjects in Beijing. Chin J Hypertens. 2005; 13: 115-119.
7. Sun ZQ, Zheng LQ, Wei YD, et al. Prevalence and risk factors of the rural adult people rehypertension status in Liaoning Province of China. Circ J 2007; 71: 550-553.
8. Zhu H, Yan W, Ge D, et al. Cardiovascular characteristics in American youth with prehypertension. AM J Hypertens. 2007; 20(10): 1051-1057.
9. Agyemang C, Van Valkengoed I, van den BJ, Stronks K. Prevalence and determinants of prehypertension among African Surinamese, Hindustani Surinamese, and White Dutch in Amsterdam, the Netherlands: the SUNSET study. Eur J Cardiovasc Prev Rehabil 2007; 14(6):775-781.
10. Greenlund KJ, Croft JB, Mensah GA: Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1990–2000. ArchIntern Med. 2004; 164: 2113–2118
11. Welborn TA , Breckenridge A , Rubinstein AH , et al . Serum insulin in essential hypertension and in peripheral vascular disease. Lancet 1966; 1(745): 1336-1337.
12. S1ater EE. Insulin resistance and hypertension. Hypertension 2004, 18 (3 Supp l): 1108 - 1114.
13. McGill JB, Haffner S, Rees TJ, Sowers JR, Tershakovec AM, Weber M. Progress and controversies: treating obesity and insulin resistance in the context of hypertension. J Clin Hypertens 2009; 11(1):36-41.
14. Edward J. Boykoa,b, Jonathan E, et al. A prospective study of glycemia, body size, insulin resistance and the risk of hypertension in Mauritius. J Hypertens 2008, 26:1742–1749.
15. Sironi AM, Pingitore A, Ghione S, et al. Early Hypertension Is Associated With Reduced Regional Cardiac Function, Insulin Resistance, Epicardial, and Visceral Fat. Hypertension 2008; 51: 282-288.
16. Player MS, Mainous AG , Diaz VA, Everett CJ. Prehypertension and insulin resistance in a nationally representative adult population. J Clin Hyperten 2007; 9(6):424-429.
17. Kanauchi M, Kanauchi K, Inoue T, Kimura K, Saito Y. Surrogate markers of insulin resistance in assessing individuals with new categories‘‘prehypertension’’and‘‘prediabetes’’. Clin Chem Lab Med 2007; 45: 35–39.
18. Sathiyapriya V, Selvaraj N, Nandeesha H, Bobby Z, Aparna A, Pavithran P. Association between protein bound sialic acid and high sensitivity C-reactive protein in prehypertension: a possible indication of underlying cardiovascular risk. Clin Exp Hypertens 2008; 30(5):367-74.
19. Gu DF, Kelly TN, Wu XG, et al. Mortality attributable to smoking in China. N Engl J Med 2009; 360:150-159.
20. Nagahama K, Inoue T, Suwazono Y, Kobayashi E, Nogawa K. Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27: 835-841.
21. Wang W, Lee ET, Fabsitz RR, Deverux R, Best L, Welty TK, Howard BV. A longitudinal study of hypertension risk factors and their relation to cardiovasculardisease: the strong heart study. Hypertension 2006; 47:403-409.
22. Bowman TS, Gaziano JM, Buring JE, Sesso HD. A prospective study of cigarette smoking and risk of incident hypertension in women. J Am Coll Cardiol 2007; 50: 2085-2092.
23. Halperin RO. Gaziano JM. Sesso HD. Smoking and the risk of incident hypertension in middle-aged and older men. Am J Hypertens 2008; 26(2):148-152.
24. Primatesta P, Falaschetti E, Gupta S, Marmot MG, Poulter NR. Association between smoking and blood pressure: Evidence from the health survey for England. Hypertension 2001; 37: 187 -193.
25. Bautista LE, Lópex-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19(5): 857-861.
26. Sung KC, Suh JY, Kim BS, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16(6): 429-433.
27. Lakoski SG, Herrington DM, Siscovick DM, Hulley SB. C-reactive protein concentration and incident hypertension in young adults: the CARDIA study. Arch Intern Med 2006; 166(3): 345-349.
28. Ridker PM, Hennekens CH, Buring JE, Rifal N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
29. King DE, Egan BM, Mainous AG 3rd, Geesey ME. Elevation of C-reactive protein in people with prehypertension. J Clin Hyperten 2004; 6(10):562-528.
30. Sathiyapriya V, Selvaraj N, Nandeesha H, Bobby Z, Aparna A, Pavithran P. Association between protein bound sialic acid and high sensitivity C-reactive protein in prehypertension: a possible indication of underlying cardiovascular risk. Clin Exp Hypertens 2008; 30(5):367-374.
31. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atheroscle2 rotic disease: The ATTICA Study. Am J Hyptertens 2004;17(7): 568-573.
32. DeSouza CA, Dengel DR, Macko RF, Cox K, Seals DR. Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens 1997; 10:1335-1341.
33. Hlubocka Z, Umnerova V, Heller S, et al. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. J Human Hypertens 2002; 16:557-562.
34. Cottone S, Mule G, Nardi E, et al. C-reactive protein and intercellular adhesion molecule-1 are stronger predictors of oxidant stress than blood pressure in established hypertension. J Hypertens 2007; 25: 423-428.
35. Miller MA, Kerry SM, Cook DG, Cappuccio FP. Cellular adhesion molecules and blood pressure interaction with sex in a multi-ethnic population. J Hypertens 2004; 22:705-711.
36. Schiffrin EL, Touyz RM. Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade. J Am Coll Cardiol 2003; 42:911-913.
37.Pastore L, Tessitore A, Martinotti S, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999; 100:1646-1652.
38. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-1052.
39. Liao TD, Yang XP, Liu YH, et al. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension 2008; 52:256-263.
40. Van den Born BH , Koopmans RP, van Montfrans GA. The Renin-Angiotensin System in Malignant Hypertension Revisited: Plasma Renin Activity, Microangiopathic Hemolysis, and Renal Failure in Malignant Hypertension. Am J Hypertens 2007; 20, 900-906.
41.王忠,郭淑霞,田银君等.哈萨克族原发性高血压患者血浆肾素、AngⅡ、醛固酮水平的分析.《临床荟萃》2006;21(19):1398-1399.
42. He J, Klag MJ, Appel LJ, Charleston J, Whelton PK. The renin-angiotensin system and blood pressure: differences between blacks and whites. Am J Hypertens 1999;12: 555-562.
43. Ruddy MC, Bialy GB, Malka ES, Lacy CR, Kostis JB. The relationship of plasma rennin activity to clinic and ambulatory blood pressure in elderly people with isolated systolic hypertension. J hypertens1988; 6(suppl 4): S412-S415.
44. Marco MD, Simone GD, Roman MJ, et al. Cardiovascular and Metabolic Predictors of Progression of Prehypertension Into Hypertension. Hypertension 2009; 54:974-980.
45.Wong ND. Metabolic syndrome cardiovascular risk assessment and management. Am J Cardiovasc Drugs 2007; 7:259-272.
46.赵冬,李翠芬,王薇等,正常高值血压人群10年心血管病发病危险的分析.中华老年心脑血管病杂志2006; 8(11): 730-733.
47.周慧,胡晓抒,郭志荣登.高血压前期的血压水平与多代谢异常的关系.中华流行病学杂志2005; 26(11): 892-896.
48.梁柳娟,梁志忠,邓国任等.社区高血压多代谢异常的横断面研究.现代预防医学2005; 32(2): 1617-1619.
49. Yu DH, Huang JF, Hu DS, et al. Association Between Prehypertension and Clustering of Cardiovascular Disease Risk Factors Among Chinese Adults. J Cardiovasc PharmacolTM 2009; 53:388-400.
50.Bo S, Gambino R, Gentile L, Pagano G, Rosato R, Saracco GM,et al. High-normal blood pressure is associated with a cluster of cardiovascular and metabolic risk factors: a population-based study. J Hypertens 2009, 27:102-108.
51.Nakanishini N, Li WJ, Fukuda H, Takatorige T, Suzuki K, Tatara K. Multiple Risk Factor Clustering and Risk of Hypertension in Japanese Male Office Workers. Industrial Health 2003; 41, 327-331
52. Tozawa M, Iseki K, Iseki C, et al. Impact of Multiple Risk Factor Clustering on the Elevation of Blood Pressure. Hypertens Res 2002; 25: 811-816.
53. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38: 399-403
54. Schillaci G, Pirro M, Gemelli F et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens 2003; 21: 1841-1846
55. Stumpf C, John S, Jukic J et al. Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens2005; 23: 995-1000
56. King DE, Egan BM, Mainous AG, Geesey ME. Elevation of C-reactive protein in people with prehypertension. J Clin Hypertension 2004; 6:562-568.
57. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am J Hypertens 2004; 17: 568-573.
58. Zhang Y, Lee ET, Devereux RB, Yeh J, Best LG, Fabsitz RR, et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: The Strong Heart Study. Hypertension 2006; 47: 410- 414.
59. Smith SC. Multiple risk factors for cardiovascular disease and diabetes mellitus. Am J Med 2007; 120: S3 -S11.
60. Svetkey LP, Simons-Morton DG, Proschan MA, Sacks FM, Conlin PR, Harsha D, et al. DASH-Sodium Collaborative Research Group: Effect of the dietary approaches to stop hypertension (DASH) diet and reduced sodium intake on blood pressure control. J Clin Hypertens 2004; 6: 373 - 381.
61.吴兆苏,姚崇华,赵冬,等.我国多省市心血管病趋势及决定因素的人群监测(中国MONICA方案)Ⅰ:发病率和死亡率的监测结果.中华心血管病杂志1997; 25: 6-11.
62. Vasan PS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291-1297.
63.王薇,赵冬,刘静,等.中国35~64岁人群血压水平与10年心血管病发病危险的前瞻性研究.中华内科杂志2004; 43 (10):730-734.
64. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular diseases in the Asia-Pacific region. J Hypertens 2003; 21: 707-716.
65.王薇,赵冬,孙佳艺,等.中国11省市队列人群危险因素与不同类型心血管病发病危险的比较.中华心血管病杂志, 2006; 34(12): 1133-1135.
66 Zhang Y, Galloway JM, Welty TK, et al. Incidence and Risk Factors for Stroke in American Indians. The Strong Heart Study. Circulation 2008; 118: 1577-1584.
67. Domanski MJ, Davis BR, Pfeffer MA, et al. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension 1999; 34: 375-380.
68.俞玲,浦晓东,陈慧等.人群脉压与心脑血管病发病的研究.心血管康复医学杂志2008; 17(2):107-110.
69. Wolf PA, D’Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke: the Framingham Study. JAMA 1988; 259: 1025–1029.
70.张栓虎.我国居民吸烟与脑卒中关系的Meta-analysis.中国慢性病预防与控制2000; 8(4):156-157.
71. Kurth T, Kase CS, Berger K, Schaeffner ES, Buring JE, Gaziano JM. Smoking and the Risk of Hemorrhagic Stroke in Men Stroke 2003; 34: 1151-1155;
72. DjousséL, Ellison RC, Beiser A, Scaramucci A, D’Agostino RB, Wolf PA. Alcohol Consumption and Risk of Ischemic Stroke. The Framingham Study. Stroke 2002; 33:907-912.
73.仇成轩,钟衍军,刘蔚华,等.我国居民饮酒与脑卒中关系的Meta-analysis研究.预防医学情报杂志1998; 14(1):16-18.
74. Reynold K, Lewis BL, Nolen DJ, et al. Alcohol consumption and risk of stroke. JAMA 2003; 289: 578-588.
75. Jood k, Jern C, Wilhelmsen L, Rosengren A. Body Mass Index in Mid-Life Is Associated With a First Stroke in Men. A Prospective Population Study Over 28 Years. Stroke 2004; 35:2764-2769.
76. Hu G, Tuomilehto J, Silventoinen K, Sarti C, Mannisto S , Pekka Jousilahti P. Body Mass Index, Waist Circumference, and Waist-Hip Ratio on the Risk of Total and Type-Specific Stroke. Arch Zntern Med 2007, 167: 1420-1427.
77. Song YM, Sung J, Smith GD, Ebrahim S. Body Mass Index and Ischemic and Hemorrhagic Stroke. A Prospective Study in Korean Men. Stroke 2004; 35: 831-836.
78. Funada S, Shimazu T, Kakizaki M, et al. Body mass index and cardiovascular disease mortality in Japan: the Ohsaki Study. Preventive Medicine 2008; 47(1):66-70.
79. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis epidemiology pathophysiology and management. JAMA 2002;287 (19): 2570-22581.
80.Sacco RL, Benson RT, Kargman DE, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 2001; 285(21):2729-2735.
81. Shahar E, Chambless LE, Rosamond WD, et al; Atherosclerosis Risk in Communities Study. Plasma lipid profile and incident ischemic stroke: theAtherosclerosis. Risk in Communities (ARIC) study. Stroke 2003; 34(3): 623-631.
82. Willey JZ, Xu Q, Boden-Albala B, et al. Lipid Profile Components and Risk of Ischemic Stroke. Arch Neurol 2009; 66(11):1400-1406.
83. Soyama Y, Miura K, Morikawa Y, et al. High-Density Lipoprotein Cholesterol and Risk of Stroke in Japanese Men and Women.The Oyabe Study. Stroke 2003; 34:863-868.
84. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 2008; 196(2):489-496.
85. Bonaventurea A, Kurtha T, Picoa F, et al. Triglycerides and risk of hemorrhagic stroke vs. ischemic vascular events: The Three-City Study. Atherosclerosis 2009; doi: 10.1016.
86. Mulvihill NT, Foley JB. Inflammation in acute coronary syndromes. Heart 2002; 87: 201-204.
87. Lindsberg PJ, Grau AJ. Inflammation and Infections as Risk Factors for Ischemic Stroke. Stroke 2003; 34:2518-2532.
88. Wakugawa Y, Kiyohara Y, Tanizaki Y, et al. C-Reactive Protein and Risk of First-Ever Ischemic and Hemorrhagic Stroke in a General Japanese Population. The Hisayama Study. Stroke 2006; 37:27-32.
89. Ridker PM ,Cushman M ,Stampfer MJ , et al . Inflammation, aspirin , and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336 (14): 973-979.
90. Rost NS, Wolf PA , Kase CS , et al . Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack. the Framingham study. Stroke 2001; 32(11): 2575-2579.
1. Robinson SC,Brucer M. Range of normal blood pressure: a statistical and clinical study of 11,383 persons. Arch Intern Med 1939;64:409-444.
2. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
3. Lewington S, Clarke R,Qizilbash N, Peto R,Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
4. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358(9294): 1682-1686.
5.王薇,赵冬,刘静等.中国35～64岁人群血压水平与10年心血管病发病危险的前瞻性研究.中华内科杂志2004; 43(10):730-734.
6. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
7. Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med 2004; 164: 2126-2134.
8. Aekplakorn W, Abbott-Klafter J, Khonputsa P, et al. Prevalence and management of prehypertension and hypertension by geographic regions of Thailand: the Third National Health Examination Survey, 2004. J Hypertens 2008; 26(2):191-198.
9. Choi KM, Park HS, Han JH, et al. Prevalence of prehypertension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001. J Hypertens 2006, 24:1515-1521.
10. Tsai PS, Ke TL, Huang CJ, Tsai JC, Chen PL. Prevalence and determinants of prehypertension status in the Taiwanese general population. J Hypertens 2005; 23:1355-13606.
11.赵冬,李翠芬,王薇等.正常高值血压人群10年心血管病发病危险的分析.中华老年心脑血管病杂志2006; 8(11): 730-733.
12. Sun ZQ, Zheng LQ, Wei YD, Li J, Zhang XZ, Zhang XQ, et al. The prevalence of prehypertension and hypertension among rural adults in Liaoning Province of China. Clin Cardiol 2007; 30(4): 183-187.
13. Chockalingam A, Ganesan N, Venkatesan S, et al. Patterns and predictors of prehypertension among“healthy”urban adults in India. Angiology 2005; 56(5): 557-563.
14. Ramos E, Barros H. Prevalence of hypertension in 13-year-old adolescents in Porto, Portugal. Rev Port Cardiol 2005; 24(9): 1075-1087.
15. Itamar Grotto, Ehud Grossman, Michael Huerta, Yehonatan Sharabi. Prevalence of Prehypertension and Associated Cardiovascular Risk Profiles Among Young Israeli Adults. Hypertension 2006; 48: 254-259.
16. Greenlund KJ, Croft JB,Mensah GA. Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999–2000. ArchIntern Med 2004;164:2113-2118.
17. Mainous AG, Everett CJ, Liszka H, King DE,Egan BM. Prehypertension and mortality in a nationally representative cohort. Am J Cardiol 2004; 94: 1496-1500.
18. Hsia J, Margolis KL, Eaton CB, et al. Prehypertension and cardiovascular disease risk in the Women’s Health Initiative. Circulation 2007; 115: 855–860.
19. Zhang Y, Lee ET, Devereux RB, et al. Prehypertension, diabetes, and cardiovascular disease risk in a population based sample: the Strong Heart Study. Hypertension 2006; 47: 410–414.
20. Agyemanga C, Valkengoeda IV, Bornb BJ van den, Stronksa K. Prevalence and determinants of prehypertension among African Surinamese, Hindustani Surinamese, and White Dutch in Amsterdam, the Netherlands: the SUNSET study. Eur J Physical Med Rehab 2007; 14:775-781.
21. King DE, Egan BM, Mainous AG 3rd, Geesey ME. Elevation of C-reactive protein in people with prehypertension. J Clin Hyperten 2004; 6(10):562-528.
22. Sathiyapriya V, Selvaraj N, Nandeesha H, Bobby Z, Aparna A, Pavithran P. Association between protein bound sialic acid and high sensitivity C-reactive protein in prehypertension: a possible indication of underlying cardiovascular risk. Clin Exp Hypertens 2008; 30(5): 367-374.
23. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am J Hyptertens 2004;17(7): 568–573.
24. Smith SC. Multiple Risk Factors for Cardiovascular Disease and Diabetes Mellitus. Am J Med 2007; 120(3A): S3–S11.
25. Wong ND. Metabolic Syndrome Cardiovascular Risk Assessment and Management. Am J Cardiovasc Drugs 2007; 7 (4): 259-272.
26.周慧,胡晓抒,郭志荣登.高血压前期的血压水平与多代谢异常的关系.中华流行病学杂志2005; 26(11):892-896.
27.梁柳娟,梁志忠,邓国任等.社区高血压多多代谢异常的横断面研究.现代预防医学2005;32(2):1617-1619.
28. Yu DH, Huang JF, Hu DS, et al. Association Between Prehypertension and Clustering of Cardiovascular Disease Risk Factors Among Chinese Adults. JCardiovasc PharmacolTM 2009; 53: 388–400.
29. Bo S, Gambino R, Gentile L, Pagano G, Rosato R, Saracco GM, et al. High-normal blood pressure is associated with a cluster of cardiovascular and metabolic risk factors: a population-based study. J Hypertens 2009, 27:102-108.
30. Kanauchi M, Kanauchi K, Hashimoto T, Saito Y. Metabolic syndrome and new category 'pre-hypertension' in a Japanese population. CMRO 2004; 20(9): 1365-1370.
31.孙佳艺、赵冬、王薇等。北京地区2740人的血压水平(1992-2002)变化情况.高血压杂志2005; 13(2):115-119.
32. Gu D, Wildman RP, Wu X, et al. Incidence and predictors of hypertension over
8 years among Chinese men and women. J Hypertens 2007; 25:517–523.
33. Qureshi AI, Suri MFK, Kirmani JF, Divani AA, Mohammad Y. Is Prehypertension a Risk Factor for Cardiovascular Diseases? Stroke 2005; 36:1859-1863.
34. Leung H, Wang JJ, Rochtchina E, et al. Relationships between age, blood pressure, and retinal vessel diameters in an older population. Inves Ophthalmol Vis Sci 2003; 44: 2900-2904.
35. Wong TY, Klein R, Klein BE, Meuer SM, Hubbard LD. Retinal vessel diameters and their associations with age and blood pressure. Invest Ophthalmo Vis Sci 2003; 44: 4644-4650.
36. Ikram MK,Witteman JC,Vingerling JR,Breteler MM, Hofman A, de Jong PT. Retinal vessel diameters and risk of hypertension: the Rotterdam Study. Hypertension 2006; 47: 189-194.
37. Manios E,Tsivgoulis G, Koroboki E,et al. Impact of prehypertension on common carotid artery intima-media thickness and left ventricular mass. Stroke 2009; 40: 1515-1518.
38. Pletcher MJ, Bibbins-Domingo K, Lewis CE, et al. Prehypertension during young adulthood and coronary calcium later in life. Ann Intern Med 2009; 149: 91–99.
39. Toikka JO, Laine H, Ahotupa M, et al. Increased arterial intima-media thickness and in vivo LDL oxidation in young men with borderline hypertension. Hypertension 2000; 36:929.
40.印小荣,段宝祥,何晓虹,等.血压正常高值对动脉内膜-中膜厚度的影响.南京医科大学学报2005; 25:813-816.
41.Markus MR, Stritzke J, Lieb W, et al. Implications of persistent prehypertension for ageing-related changes in left ventricular geometry and function: the MONICA/KORA Augsburg study. J Hypertens 2008; 26: 2040–2049.
42. Vasan PS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291-1297.
43. Qureshi AI, Suri MFK, Kirmani JF, Divani AA, Mohammad Y. Is Prehypertension a Risk Factor for Cardiovascular Diseases? Stroke 2005; 36:1859-1863.
44. Adler AI, Straton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complication of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412-419.
45. Mainous III AG, Everett CJ, Liszka H, et al. Prehypertension and mortality in a nationally representative cohort. The American Journal of Cardiology 2004; 94:1496-1500.
46. Gu D, Chen J, Wu X, et al. Prehypertension and risk of cardiovascular disease in Chinese adults. J Hypertens 2009; 27:721-729.
47.国家“十五”攻关冠心病、脑卒中综合危险因素危险度评估及干预研究课题组(武阳丰).国人缺血性心血管病发病危险的评估方法及简易评估工具的开发研究.中华心血管病杂志2003;31: 893-901.
48. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336: 1117-1124.
49. Elmer PJ, Obarzanek J, Vollmer WM, et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-Month results of a randomized Trial. Ann Intern Med 2006; 144: 485-495.
50. Maruthur NM, Wang NY, Appel LJ. Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER Trial. Circulation 2009; 119: 2026-2031.
51. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007; 334:885-888.
52. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354, 1685-1697.
53. Lüders S,Schrader J, Berger J, et al. The PHARAO study: prevention of hypertension with the angiotensin converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008; 26: 1487-1496.
54. Chobanian AV. Prehypertension revisited. Hypertension 2006; 48: 812-814.
55. Schunkert H. Pharmacotherapy for prehypertension—mission accomplished? N Engl J Med 2006;354:1742-1744.
2. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular diseases in the Asia-Pacific region. J Hypertens 2003; 21: 707-716.
3. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; 289(19): 2560-2572.
4.中国高血压防治指南修订委员会.中国高血压防治指南2005年修订版[ R] .北京:中国高血压防治指南修订委员会, 2005.
5. Lewington S,Clarke R,Qizilbash N,et al .Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
6.王薇,赵冬,刘静,等.中国35～64岁人群血压水平与10年心血管病发病危险的前瞻性研究.中华内科杂志2004; 43 (10):730-734
7.赵冬,李翠芬,王薇,等.正常高值血压人群10年心血管病发病危险的分析.中华老年心脑血管病杂志2006;8 (11): 730-733.
8.孙佳艺、赵冬、王薇等.北京地区2740人的血压水平(1992-2002)变化情况.高血压杂志2005; 13(2):115-119.
9. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: A cohort study. Lancet 2001; 358: 1682-1686.
10. Ueshima H, Zhang X, Choudhury SR. Epidemiology of hypertension in China and Japan. J Hum Hypertens 2000; 14, 765-769.
11.周慧,胡晓抒,郭志荣登.高血压前期的血压水平与多代谢异常的关系.中华流行病学杂志2005; 26(11):892-896.
12.梁柳娟,梁志忠,邓国任等.社区高血压多代谢异常的横断面研究.现代预防医学2005;32(2):1617-1619.
13. Hsia J, Margolis KL, Eaton CB, et al. Prehypertension and cardiovascular disease risk in the Women’s Health Initiative. Circulation 2007; 115: 855-860.
14. Grotto I, Grossman E, Huerta M, Sharabi Y. Prevalence of prehypertension and associated cardiovascular risk profiles among young Israeli adults. Hypertension 2006; 48: 254–259.
15. Galeen FX. Cell adhesion molecules in hypertension: endothelial markers of vascular injury and predictors of target organ damage? J Hypertens 2002; 20: 871-877.
16.阿祥仁,张鑫生,王立萍.高原地区健康老年人同型半胱氨酸水平与血管内皮细胞功能的相关性.中华老年医学杂志2006; 25(2):123-124.
17.Freestone B, Gustafsson F, Chong AY, Corell P, Kistorp C, Hildebrandt P, Lip GY. Influence of atrial fibrillation on plasma von willebrand factor, soluble E-selectin,and N-terminal pro B-type natriuretic peptide levels in systolic heart failure. Chest 2008; 133(5):1203-1208.
18.Spencer CG, Felmeden DC, Blann AD, Lip GY. Haemorheological, platelet and endothelial indices in relation to global measures of cardiovascular risk in hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. J Intern Med. 2007 ; 261(1): 82-90.
19.Schillaci G, Pirro M, Gemelli F, et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens 2003; 21(10):1841-1846.
20.Bautista LE, Lópex-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens. 2001; 19(5): 857-861.
21. Sung KC, Suh JY, Kim BS, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16(6):429-433.
22. Lakoski SG, Herrington DM, Siscovick DM, Hulley SB. C-reactive protein concentration and incident hypertension in young adults: the CARDIA study. Arch Intern Med 2006; 166(3):345-349.
23. Davey Smith G, Lawlor DA, Harbord R, et al. Association of C-reactive protein with blood pressure and hypertension life course confounding and Mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 2005; 25:1051-1056.
24. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-2951.
25. Miller MA, Kerry SM, Cook DG, Cappuccio FP. Cellular adhesion molecules and blood pressure interaction with sex in a multi-ethnic population. J Hypertens 2004; 22:705–711.
26. DeSouza CA, Dengel DR, Macko RF, Cox K, Seals DR. Elevated evels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens 1997; 10: 1335-1341.
27. He J, Klag MJ, Wu ZL, Whelton PK. Stroke in the People's Republic of China: I. Geographic Variations in Incidence and Risk Factors. Stroke 1995; 26(12):2222-2227.
28. WHO. Global burden of disease 2002: deaths by age, sex and cause for the year 2002. Geneva, Switzerland: Word Health Organization; 2003.
29.Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular disease: Part II: variation in cardiovascular disease by specific ethnic groups and geographic regions strategies. Circulation 2001; 104:2855-2864.
30. Whelton PK, He J. Blood pressure reduction. In Manson JE, Buring JE, Ridker PM, Gaziano JM editors. Clinical trials in cardiovascular disease. 2nd ed. Philadelphia: Elsevier Saunders 1999; 282-296.
31. Zhang, C. The role of inflammatory cytokines in endothelial dysfunction. Basic Research in Cardiology 2008; 103(5): 398-406.
32. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation, Part I. Circulation 2003; 108: 1917-1923.
33. Ridker PM, Hennekens CH, Buring JE, Rifal N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 2000; 342: 836-843.
34. Mulvihill NT, Foley JB. Inflammation in acute coronary syndromes. Heart 2002; 87: 201-204.
35. Lindsberg PJ, Grau AJ. Inflammation and Infections as Risk Factors for Ischemic Stroke. Stroke 2003; 34: 2518-2532
36.Wakugawa Y, Kiyohara Y, Tanizaki Y, et al. C-Reactive Protein and Risk of First-Ever Ischemic and Hemorrhagic Stroke in a General Japanese Population. The Hisayama Study. Stroke 2006; 37:27-32.
37.张永红,佟伟军,张宏伟,等.通辽市农牧区蒙古族居民高血压调查报告.中国公共卫生2003;19(11):1358-1359.
1.丁元林等主编.《卫生统计学》[M].科学出版社2008.
2.中国高血压防治指南修订委员会.中国高血压防治指南2005年修订版[R] .北京:中国高血压防治指南修订委员会, 2005.
3. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; 289(19): 2560-2572.
4.中国疾病控制司编写.中国成人超重和肥胖症预防与控制指南<试行>.中国人民卫生出版社2003.
5.中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南.中华心血管病杂志2007; 35: 390-419.
6. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance andβ2 cell function from fasting plasma glucose and insulin concent rations in man. Diabetologia 1985; 28: 412-419.
7.高惠璇.《SAS系统. SAS/ETS软件使用手册》[M].中国统计出版社2001.
8. Hosmer DW, Lemeshow S. Applied logistic regression, 2nd-edn. New York: John Wiley & Sons; 2000.
9. Spiegelman D, Hertzmark E, Wand HC. Point and interval estimates of partial population attributable risks in cohort studies: examples and software. Cancer Causes Control 2007; 18:571–579.
1. Sun ZQ, Zheng LQ, Wei YD, et al. The Prevalence of Prehypertension and Hypertension Among Rural Adults in Liaoning Province of China. Clin Cardiol. 2007; 30, 183-187.
2. Tsai PS, Ke TL, Huang CJ, Tsai JC, Chen PL. Prevalence and determinants of prehypertension status in the Taiwanese general population. J Hypertens 2005; 23: 1355-13606.
3. Wang Y, Wang Q J. The prevalence of prehypertension and hypertension among US adults according to the New Joint National Committee Guidelines. Arch Intern Med. 2004; 164: 2126-2134.
4. Aekplakorn W, Abbott-Klafter J, Khonputsa P, et al. Prevalence and management of prehypertension and hypertension by geographic regions of Thailand: the Third National Health Examination Survey, 2004. J Hypertens 2008; 26(2):191-198.
5. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: A cohort study. Lancet 2001; 358: 1682- 1686.
6. Sun J , Zhao D, Wang W, Liu J, Wu C, Wang W. The change of blood pressure during ten years (1992-2002) in 2740 subjects in Beijing. Chin J Hypertens. 2005; 13: 115-119.
7. Sun ZQ, Zheng LQ, Wei YD, et al. Prevalence and risk factors of the rural adult people rehypertension status in Liaoning Province of China. Circ J 2007; 71: 550-553.
8. Zhu H, Yan W, Ge D, et al. Cardiovascular characteristics in American youth with prehypertension. AM J Hypertens. 2007; 20(10): 1051-1057.
9. Agyemang C, Van Valkengoed I, van den BJ, Stronks K. Prevalence and determinants of prehypertension among African Surinamese, Hindustani Surinamese, and White Dutch in Amsterdam, the Netherlands: the SUNSET study. Eur J Cardiovasc Prev Rehabil 2007; 14(6):775-781.
10. Greenlund KJ, Croft JB, Mensah GA: Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1990–2000. ArchIntern Med. 2004; 164: 2113–2118
11. Welborn TA , Breckenridge A , Rubinstein AH , et al . Serum insulin in essential hypertension and in peripheral vascular disease. Lancet 1966; 1(745): 1336-1337.
12. S1ater EE. Insulin resistance and hypertension. Hypertension 2004, 18 (3 Supp l): 1108 - 1114.
13. McGill JB, Haffner S, Rees TJ, Sowers JR, Tershakovec AM, Weber M. Progress and controversies: treating obesity and insulin resistance in the context of hypertension. J Clin Hypertens 2009; 11(1):36-41.
14. Edward J. Boykoa,b, Jonathan E, et al. A prospective study of glycemia, body size, insulin resistance and the risk of hypertension in Mauritius. J Hypertens 2008, 26:1742–1749.
15. Sironi AM, Pingitore A, Ghione S, et al. Early Hypertension Is Associated With Reduced Regional Cardiac Function, Insulin Resistance, Epicardial, and Visceral Fat. Hypertension 2008; 51: 282-288.
16. Player MS, Mainous AG , Diaz VA, Everett CJ. Prehypertension and insulin resistance in a nationally representative adult population. J Clin Hyperten 2007; 9(6):424-429.
17. Kanauchi M, Kanauchi K, Inoue T, Kimura K, Saito Y. Surrogate markers of insulin resistance in assessing individuals with new categories‘‘prehypertension’’and‘‘prediabetes’’. Clin Chem Lab Med 2007; 45: 35–39.
18. Sathiyapriya V, Selvaraj N, Nandeesha H, Bobby Z, Aparna A, Pavithran P. Association between protein bound sialic acid and high sensitivity C-reactive protein in prehypertension: a possible indication of underlying cardiovascular risk. Clin Exp Hypertens 2008; 30(5):367-74.
19. Gu DF, Kelly TN, Wu XG, et al. Mortality attributable to smoking in China. N Engl J Med 2009; 360:150-159.
20. Nagahama K, Inoue T, Suwazono Y, Kobayashi E, Nogawa K. Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27: 835-841.
21. Wang W, Lee ET, Fabsitz RR, Deverux R, Best L, Welty TK, Howard BV. A longitudinal study of hypertension risk factors and their relation to cardiovasculardisease: the strong heart study. Hypertension 2006; 47:403-409.
22. Bowman TS, Gaziano JM, Buring JE, Sesso HD. A prospective study of cigarette smoking and risk of incident hypertension in women. J Am Coll Cardiol 2007; 50: 2085-2092.
23. Halperin RO. Gaziano JM. Sesso HD. Smoking and the risk of incident hypertension in middle-aged and older men. Am J Hypertens 2008; 26(2):148-152.
24. Primatesta P, Falaschetti E, Gupta S, Marmot MG, Poulter NR. Association between smoking and blood pressure: Evidence from the health survey for England. Hypertension 2001; 37: 187 -193.
25. Bautista LE, Lópex-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19(5): 857-861.
26. Sung KC, Suh JY, Kim BS, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16(6): 429-433.
27. Lakoski SG, Herrington DM, Siscovick DM, Hulley SB. C-reactive protein concentration and incident hypertension in young adults: the CARDIA study. Arch Intern Med 2006; 166(3): 345-349.
28. Ridker PM, Hennekens CH, Buring JE, Rifal N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
29. King DE, Egan BM, Mainous AG 3rd, Geesey ME. Elevation of C-reactive protein in people with prehypertension. J Clin Hyperten 2004; 6(10):562-528.
30. Sathiyapriya V, Selvaraj N, Nandeesha H, Bobby Z, Aparna A, Pavithran P. Association between protein bound sialic acid and high sensitivity C-reactive protein in prehypertension: a possible indication of underlying cardiovascular risk. Clin Exp Hypertens 2008; 30(5):367-374.
31. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atheroscle2 rotic disease: The ATTICA Study. Am J Hyptertens 2004;17(7): 568-573.
32. DeSouza CA, Dengel DR, Macko RF, Cox K, Seals DR. Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens 1997; 10:1335-1341.
33. Hlubocka Z, Umnerova V, Heller S, et al. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. J Human Hypertens 2002; 16:557-562.
34. Cottone S, Mule G, Nardi E, et al. C-reactive protein and intercellular adhesion molecule-1 are stronger predictors of oxidant stress than blood pressure in established hypertension. J Hypertens 2007; 25: 423-428.
35. Miller MA, Kerry SM, Cook DG, Cappuccio FP. Cellular adhesion molecules and blood pressure interaction with sex in a multi-ethnic population. J Hypertens 2004; 22:705-711.
36. Schiffrin EL, Touyz RM. Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade. J Am Coll Cardiol 2003; 42:911-913.
37.Pastore L, Tessitore A, Martinotti S, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999; 100:1646-1652.
38. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-1052.
39. Liao TD, Yang XP, Liu YH, et al. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension 2008; 52:256-263.
40. Van den Born BH , Koopmans RP, van Montfrans GA. The Renin-Angiotensin System in Malignant Hypertension Revisited: Plasma Renin Activity, Microangiopathic Hemolysis, and Renal Failure in Malignant Hypertension. Am J Hypertens 2007; 20, 900-906.
41.王忠,郭淑霞,田银君等.哈萨克族原发性高血压患者血浆肾素、AngⅡ、醛固酮水平的分析.《临床荟萃》2006;21(19):1398-1399.
42. He J, Klag MJ, Appel LJ, Charleston J, Whelton PK. The renin-angiotensin system and blood pressure: differences between blacks and whites. Am J Hypertens 1999;12: 555-562.
43. Ruddy MC, Bialy GB, Malka ES, Lacy CR, Kostis JB. The relationship of plasma rennin activity to clinic and ambulatory blood pressure in elderly people with isolated systolic hypertension. J hypertens1988; 6(suppl 4): S412-S415.
44. Marco MD, Simone GD, Roman MJ, et al. Cardiovascular and Metabolic Predictors of Progression of Prehypertension Into Hypertension. Hypertension 2009; 54:974-980.
45.Wong ND. Metabolic syndrome cardiovascular risk assessment and management. Am J Cardiovasc Drugs 2007; 7:259-272.
46.赵冬,李翠芬,王薇等,正常高值血压人群10年心血管病发病危险的分析.中华老年心脑血管病杂志2006; 8(11): 730-733.
47.周慧,胡晓抒,郭志荣登.高血压前期的血压水平与多代谢异常的关系.中华流行病学杂志2005; 26(11): 892-896.
48.梁柳娟,梁志忠,邓国任等.社区高血压多代谢异常的横断面研究.现代预防医学2005; 32(2): 1617-1619.
49. Yu DH, Huang JF, Hu DS, et al. Association Between Prehypertension and Clustering of Cardiovascular Disease Risk Factors Among Chinese Adults. J Cardiovasc PharmacolTM 2009; 53:388-400.
50.Bo S, Gambino R, Gentile L, Pagano G, Rosato R, Saracco GM,et al. High-normal blood pressure is associated with a cluster of cardiovascular and metabolic risk factors: a population-based study. J Hypertens 2009, 27:102-108.
51.Nakanishini N, Li WJ, Fukuda H, Takatorige T, Suzuki K, Tatara K. Multiple Risk Factor Clustering and Risk of Hypertension in Japanese Male Office Workers. Industrial Health 2003; 41, 327-331
52. Tozawa M, Iseki K, Iseki C, et al. Impact of Multiple Risk Factor Clustering on the Elevation of Blood Pressure. Hypertens Res 2002; 25: 811-816.
53. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38: 399-403
54. Schillaci G, Pirro M, Gemelli F et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens 2003; 21: 1841-1846
55. Stumpf C, John S, Jukic J et al. Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens2005; 23: 995-1000
56. King DE, Egan BM, Mainous AG, Geesey ME. Elevation of C-reactive protein in people with prehypertension. J Clin Hypertension 2004; 6:562-568.
57. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am J Hypertens 2004; 17: 568-573.
58. Zhang Y, Lee ET, Devereux RB, Yeh J, Best LG, Fabsitz RR, et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: The Strong Heart Study. Hypertension 2006; 47: 410- 414.
59. Smith SC. Multiple risk factors for cardiovascular disease and diabetes mellitus. Am J Med 2007; 120: S3 -S11.
60. Svetkey LP, Simons-Morton DG, Proschan MA, Sacks FM, Conlin PR, Harsha D, et al. DASH-Sodium Collaborative Research Group: Effect of the dietary approaches to stop hypertension (DASH) diet and reduced sodium intake on blood pressure control. J Clin Hypertens 2004; 6: 373 - 381.
61.吴兆苏,姚崇华,赵冬,等.我国多省市心血管病趋势及决定因素的人群监测(中国MONICA方案)Ⅰ:发病率和死亡率的监测结果.中华心血管病杂志1997; 25: 6-11.
62. Vasan PS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291-1297.
63.王薇,赵冬,刘静,等.中国35~64岁人群血压水平与10年心血管病发病危险的前瞻性研究.中华内科杂志2004; 43 (10):730-734.
64. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular diseases in the Asia-Pacific region. J Hypertens 2003; 21: 707-716.
65.王薇,赵冬,孙佳艺,等.中国11省市队列人群危险因素与不同类型心血管病发病危险的比较.中华心血管病杂志, 2006; 34(12): 1133-1135.
66 Zhang Y, Galloway JM, Welty TK, et al. Incidence and Risk Factors for Stroke in American Indians. The Strong Heart Study. Circulation 2008; 118: 1577-1584.
67. Domanski MJ, Davis BR, Pfeffer MA, et al. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension 1999; 34: 375-380.
68.俞玲,浦晓东,陈慧等.人群脉压与心脑血管病发病的研究.心血管康复医学杂志2008; 17(2):107-110.
69. Wolf PA, D’Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke: the Framingham Study. JAMA 1988; 259: 1025–1029.
70.张栓虎.我国居民吸烟与脑卒中关系的Meta-analysis.中国慢性病预防与控制2000; 8(4):156-157.
71. Kurth T, Kase CS, Berger K, Schaeffner ES, Buring JE, Gaziano JM. Smoking and the Risk of Hemorrhagic Stroke in Men Stroke 2003; 34: 1151-1155;
72. DjousséL, Ellison RC, Beiser A, Scaramucci A, D’Agostino RB, Wolf PA. Alcohol Consumption and Risk of Ischemic Stroke. The Framingham Study. Stroke 2002; 33:907-912.
73.仇成轩,钟衍军,刘蔚华,等.我国居民饮酒与脑卒中关系的Meta-analysis研究.预防医学情报杂志1998; 14(1):16-18.
74. Reynold K, Lewis BL, Nolen DJ, et al. Alcohol consumption and risk of stroke. JAMA 2003; 289: 578-588.
75. Jood k, Jern C, Wilhelmsen L, Rosengren A. Body Mass Index in Mid-Life Is Associated With a First Stroke in Men. A Prospective Population Study Over 28 Years. Stroke 2004; 35:2764-2769.
76. Hu G, Tuomilehto J, Silventoinen K, Sarti C, Mannisto S , Pekka Jousilahti P. Body Mass Index, Waist Circumference, and Waist-Hip Ratio on the Risk of Total and Type-Specific Stroke. Arch Zntern Med 2007, 167: 1420-1427.
77. Song YM, Sung J, Smith GD, Ebrahim S. Body Mass Index and Ischemic and Hemorrhagic Stroke. A Prospective Study in Korean Men. Stroke 2004; 35: 831-836.
78. Funada S, Shimazu T, Kakizaki M, et al. Body mass index and cardiovascular disease mortality in Japan: the Ohsaki Study. Preventive Medicine 2008; 47(1):66-70.
79. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis epidemiology pathophysiology and management. JAMA 2002;287 (19): 2570-22581.
80.Sacco RL, Benson RT, Kargman DE, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 2001; 285(21):2729-2735.
81. Shahar E, Chambless LE, Rosamond WD, et al; Atherosclerosis Risk in Communities Study. Plasma lipid profile and incident ischemic stroke: theAtherosclerosis. Risk in Communities (ARIC) study. Stroke 2003; 34(3): 623-631.
82. Willey JZ, Xu Q, Boden-Albala B, et al. Lipid Profile Components and Risk of Ischemic Stroke. Arch Neurol 2009; 66(11):1400-1406.
83. Soyama Y, Miura K, Morikawa Y, et al. High-Density Lipoprotein Cholesterol and Risk of Stroke in Japanese Men and Women.The Oyabe Study. Stroke 2003; 34:863-868.
84. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 2008; 196(2):489-496.
85. Bonaventurea A, Kurtha T, Picoa F, et al. Triglycerides and risk of hemorrhagic stroke vs. ischemic vascular events: The Three-City Study. Atherosclerosis 2009; doi: 10.1016.
86. Mulvihill NT, Foley JB. Inflammation in acute coronary syndromes. Heart 2002; 87: 201-204.
87. Lindsberg PJ, Grau AJ. Inflammation and Infections as Risk Factors for Ischemic Stroke. Stroke 2003; 34:2518-2532.
88. Wakugawa Y, Kiyohara Y, Tanizaki Y, et al. C-Reactive Protein and Risk of First-Ever Ischemic and Hemorrhagic Stroke in a General Japanese Population. The Hisayama Study. Stroke 2006; 37:27-32.
89. Ridker PM ,Cushman M ,Stampfer MJ , et al . Inflammation, aspirin , and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336 (14): 973-979.
90. Rost NS, Wolf PA , Kase CS , et al . Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack. the Framingham study. Stroke 2001; 32(11): 2575-2579.
1. Robinson SC,Brucer M. Range of normal blood pressure: a statistical and clinical study of 11,383 persons. Arch Intern Med 1939;64:409-444.
2. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
3. Lewington S, Clarke R,Qizilbash N, Peto R,Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
4. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358(9294): 1682-1686.
5.王薇,赵冬,刘静等.中国35～64岁人群血压水平与10年心血管病发病危险的前瞻性研究.中华内科杂志2004; 43(10):730-734.
6. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
7. Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med 2004; 164: 2126-2134.
8. Aekplakorn W, Abbott-Klafter J, Khonputsa P, et al. Prevalence and management of prehypertension and hypertension by geographic regions of Thailand: the Third National Health Examination Survey, 2004. J Hypertens 2008; 26(2):191-198.
9. Choi KM, Park HS, Han JH, et al. Prevalence of prehypertension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001. J Hypertens 2006, 24:1515-1521.
10. Tsai PS, Ke TL, Huang CJ, Tsai JC, Chen PL. Prevalence and determinants of prehypertension status in the Taiwanese general population. J Hypertens 2005; 23:1355-13606.
11.赵冬,李翠芬,王薇等.正常高值血压人群10年心血管病发病危险的分析.中华老年心脑血管病杂志2006; 8(11): 730-733.
12. Sun ZQ, Zheng LQ, Wei YD, Li J, Zhang XZ, Zhang XQ, et al. The prevalence of prehypertension and hypertension among rural adults in Liaoning Province of China. Clin Cardiol 2007; 30(4): 183-187.
13. Chockalingam A, Ganesan N, Venkatesan S, et al. Patterns and predictors of prehypertension among“healthy”urban adults in India. Angiology 2005; 56(5): 557-563.
14. Ramos E, Barros H. Prevalence of hypertension in 13-year-old adolescents in Porto, Portugal. Rev Port Cardiol 2005; 24(9): 1075-1087.
15. Itamar Grotto, Ehud Grossman, Michael Huerta, Yehonatan Sharabi. Prevalence of Prehypertension and Associated Cardiovascular Risk Profiles Among Young Israeli Adults. Hypertension 2006; 48: 254-259.
16. Greenlund KJ, Croft JB,Mensah GA. Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999–2000. ArchIntern Med 2004;164:2113-2118.
17. Mainous AG, Everett CJ, Liszka H, King DE,Egan BM. Prehypertension and mortality in a nationally representative cohort. Am J Cardiol 2004; 94: 1496-1500.
18. Hsia J, Margolis KL, Eaton CB, et al. Prehypertension and cardiovascular disease risk in the Women’s Health Initiative. Circulation 2007; 115: 855–860.
19. Zhang Y, Lee ET, Devereux RB, et al. Prehypertension, diabetes, and cardiovascular disease risk in a population based sample: the Strong Heart Study. Hypertension 2006; 47: 410–414.
20. Agyemanga C, Valkengoeda IV, Bornb BJ van den, Stronksa K. Prevalence and determinants of prehypertension among African Surinamese, Hindustani Surinamese, and White Dutch in Amsterdam, the Netherlands: the SUNSET study. Eur J Physical Med Rehab 2007; 14:775-781.
21. King DE, Egan BM, Mainous AG 3rd, Geesey ME. Elevation of C-reactive protein in people with prehypertension. J Clin Hyperten 2004; 6(10):562-528.
22. Sathiyapriya V, Selvaraj N, Nandeesha H, Bobby Z, Aparna A, Pavithran P. Association between protein bound sialic acid and high sensitivity C-reactive protein in prehypertension: a possible indication of underlying cardiovascular risk. Clin Exp Hypertens 2008; 30(5): 367-374.
23. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am J Hyptertens 2004;17(7): 568–573.
24. Smith SC. Multiple Risk Factors for Cardiovascular Disease and Diabetes Mellitus. Am J Med 2007; 120(3A): S3–S11.
25. Wong ND. Metabolic Syndrome Cardiovascular Risk Assessment and Management. Am J Cardiovasc Drugs 2007; 7 (4): 259-272.
26.周慧,胡晓抒,郭志荣登.高血压前期的血压水平与多代谢异常的关系.中华流行病学杂志2005; 26(11):892-896.
27.梁柳娟,梁志忠,邓国任等.社区高血压多多代谢异常的横断面研究.现代预防医学2005;32(2):1617-1619.
28. Yu DH, Huang JF, Hu DS, et al. Association Between Prehypertension and Clustering of Cardiovascular Disease Risk Factors Among Chinese Adults. JCardiovasc PharmacolTM 2009; 53: 388–400.
29. Bo S, Gambino R, Gentile L, Pagano G, Rosato R, Saracco GM, et al. High-normal blood pressure is associated with a cluster of cardiovascular and metabolic risk factors: a population-based study. J Hypertens 2009, 27:102-108.
30. Kanauchi M, Kanauchi K, Hashimoto T, Saito Y. Metabolic syndrome and new category 'pre-hypertension' in a Japanese population. CMRO 2004; 20(9): 1365-1370.
31.孙佳艺、赵冬、王薇等。北京地区2740人的血压水平(1992-2002)变化情况.高血压杂志2005; 13(2):115-119.
32. Gu D, Wildman RP, Wu X, et al. Incidence and predictors of hypertension over
8 years among Chinese men and women. J Hypertens 2007; 25:517–523.
33. Qureshi AI, Suri MFK, Kirmani JF, Divani AA, Mohammad Y. Is Prehypertension a Risk Factor for Cardiovascular Diseases? Stroke 2005; 36:1859-1863.
34. Leung H, Wang JJ, Rochtchina E, et al. Relationships between age, blood pressure, and retinal vessel diameters in an older population. Inves Ophthalmol Vis Sci 2003; 44: 2900-2904.
35. Wong TY, Klein R, Klein BE, Meuer SM, Hubbard LD. Retinal vessel diameters and their associations with age and blood pressure. Invest Ophthalmo Vis Sci 2003; 44: 4644-4650.
36. Ikram MK,Witteman JC,Vingerling JR,Breteler MM, Hofman A, de Jong PT. Retinal vessel diameters and risk of hypertension: the Rotterdam Study. Hypertension 2006; 47: 189-194.
37. Manios E,Tsivgoulis G, Koroboki E,et al. Impact of prehypertension on common carotid artery intima-media thickness and left ventricular mass. Stroke 2009; 40: 1515-1518.
38. Pletcher MJ, Bibbins-Domingo K, Lewis CE, et al. Prehypertension during young adulthood and coronary calcium later in life. Ann Intern Med 2009; 149: 91–99.
39. Toikka JO, Laine H, Ahotupa M, et al. Increased arterial intima-media thickness and in vivo LDL oxidation in young men with borderline hypertension. Hypertension 2000; 36:929.
40.印小荣,段宝祥,何晓虹,等.血压正常高值对动脉内膜-中膜厚度的影响.南京医科大学学报2005; 25:813-816.
41.Markus MR, Stritzke J, Lieb W, et al. Implications of persistent prehypertension for ageing-related changes in left ventricular geometry and function: the MONICA/KORA Augsburg study. J Hypertens 2008; 26: 2040–2049.
42. Vasan PS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291-1297.
43. Qureshi AI, Suri MFK, Kirmani JF, Divani AA, Mohammad Y. Is Prehypertension a Risk Factor for Cardiovascular Diseases? Stroke 2005; 36:1859-1863.
44. Adler AI, Straton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complication of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412-419.
45. Mainous III AG, Everett CJ, Liszka H, et al. Prehypertension and mortality in a nationally representative cohort. The American Journal of Cardiology 2004; 94:1496-1500.
46. Gu D, Chen J, Wu X, et al. Prehypertension and risk of cardiovascular disease in Chinese adults. J Hypertens 2009; 27:721-729.
47.国家“十五”攻关冠心病、脑卒中综合危险因素危险度评估及干预研究课题组(武阳丰).国人缺血性心血管病发病危险的评估方法及简易评估工具的开发研究.中华心血管病杂志2003;31: 893-901.
48. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336: 1117-1124.
49. Elmer PJ, Obarzanek J, Vollmer WM, et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-Month results of a randomized Trial. Ann Intern Med 2006; 144: 485-495.
50. Maruthur NM, Wang NY, Appel LJ. Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER Trial. Circulation 2009; 119: 2026-2031.
51. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007; 334:885-888.
52. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354, 1685-1697.
53. Lüders S,Schrader J, Berger J, et al. The PHARAO study: prevention of hypertension with the angiotensin converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008; 26: 1487-1496.
54. Chobanian AV. Prehypertension revisited. Hypertension 2006; 48: 812-814.
55. Schunkert H. Pharmacotherapy for prehypertension—mission accomplished? N Engl J Med 2006;354:1742-1744.